Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
about
Options for empagliflozin in combination therapy in type 2 diabetes mellitusDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesDipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative reviewSodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectivesHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsPractical combination therapy based on pathophysiology of type 2 diabetesImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsEffects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitusSafe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: Rationale and evidences.The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease.Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.Practical Approach to Initiating SGLT2 Inhibitors in Type 2 DiabetesIncreasing Patient Acceptance and Adherence Toward Insulin.Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
P2860
Q26745771-0037A4E7-EE62-4A21-A765-45540C5C646AQ26749281-7188EC79-24FF-4E09-9DEC-F210587DF554Q26767260-2F992DB9-9CE0-416B-A696-6FF8CC6182BAQ26767263-4F9D0D8D-0795-435A-AAF7-9F6BC87A1886Q27301948-17F9C98D-37C8-42EE-9545-891204A4E299Q28072765-663B3424-7B02-423F-90B6-12AEF760FBD1Q28076530-D2E0793C-A291-4989-9C8A-BACAD01921EFQ28080114-B42190C6-4BF8-4D04-B96F-89C2750ABE33Q28553482-7FE8293A-C802-4385-BD13-2B09F1356306Q30248634-6511AA09-2678-4CAB-876E-FA9202513C31Q30249371-32CAE5B4-7397-41E4-AF1B-439A3DE373AAQ31112303-208B17F1-831C-4FBA-AB45-3388136A5B37Q32186373-FBE1977F-7D9A-426F-8B8A-52949CF38802Q33760535-E9F13A5B-9A65-4E87-9DF3-D517DDDCD194Q33890770-9EFE7F07-DF5C-4560-A42D-4D1C2C694ACFQ36303346-BE6A9B4D-33A9-4D7B-B05C-02F38200854FQ36402095-C5D23ECF-0B76-405D-B3FC-F8B68604EC06Q36555418-A8837237-9C9F-481A-8E6F-66FEEB14504AQ37018165-771E5D3F-FB02-439E-8E35-3716884299F3Q37588847-21EDD671-FDE5-47E8-BB24-E9D9C4EA1E9BQ38619164-790B194A-112E-4EDE-B9C2-F8E29A619569Q38654762-7F94F9B2-D99D-4F8B-8C47-AF6B539552F0Q38664568-31CE4629-5FA8-48C8-A7BC-EFB95B29AF3DQ38679997-51BBD79E-DA19-45CF-91FA-703EDA377D77Q38687258-03A4D373-36E6-4B7F-A90F-579EECAB44C0Q38798654-CE67DE34-E192-4FF3-B187-6445F0B9C9CFQ38802437-1838D3C4-A83B-4D09-91B3-0130437B56B4Q38821464-EE2F6D8F-AEEA-4A04-8BA1-81EF273CEB05Q38828150-4CE20EFD-B92B-42FD-82BA-1E3FBFCF072EQ38841043-2AE98982-BFB2-457A-93E0-FABC8CE8E283Q38863649-70AF1CC8-A7D4-4BAE-BFD6-ACFB98830070Q39000603-4BD3A5BC-CAC9-4A36-93C4-12F3C7DE78CCQ39006105-07FA4CC1-083A-4DE8-AF08-25F6794889BEQ39350860-8AA067D7-3476-4189-9CE9-EC54ACE517CFQ39443326-CE72084F-8708-42AA-89C3-5DEBD8436F34Q39826453-9A0DA0DD-BF12-4107-86FF-AD36C9FE8C43Q40266818-149A8045-DB53-4A40-997C-DF87ABB66F15Q40405896-935719F3-607A-4F98-98BF-6AEA8AC6F7B3Q40550581-55A3438D-015E-4E13-A803-B41B83DCF9DAQ40581771-AC75484E-5BE0-4C96-9A65-E6FB015F745A
P2860
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of empagliflozin added ...... ind, placebo-controlled trial.
@en
Impact of empagliflozin added ...... ind, placebo-controlled trial.
@nl
type
label
Impact of empagliflozin added ...... ind, placebo-controlled trial.
@en
Impact of empagliflozin added ...... ind, placebo-controlled trial.
@nl
prefLabel
Impact of empagliflozin added ...... ind, placebo-controlled trial.
@en
Impact of empagliflozin added ...... ind, placebo-controlled trial.
@nl
P2093
P2860
P921
P356
P1476
Impact of empagliflozin added ...... ind, placebo-controlled trial.
@en
P2093
EMPA-REG BASALTM trial investigators
H J Woerle
J Rosenstock
U C Broedl
P2860
P304
P356
10.1111/DOM.12503
P577
2015-06-04T00:00:00Z